CJC-1295: Days of GH Elevation, No Regulatory Clearance

The short version

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the same signal the hypothalamus sends to the pituitary to trigger GH release. It is built on the first 29 amino acids of that natural signal, but with four chemical substitutions that make it resistant to enzymatic breakdown and, in the 'DAC' (Drug Affinity Complex) version, an additional handle that binds it to a blood protein called albumin, extending its half-life from minutes to roughly 5-8 days ^[4][7].

Human pharmacokinetic studies documented real, dose-dependent, sustained elevations in GH and IGF-1 in healthy adults — the biology works as intended ^[4][5]. But the honest file stops there. CJC-1295 was never approved by the FDA or any major regulator. Its development program was discontinued. The FDA reviewed it at the 2024 Pharmacy Compounding Advisory Committee and did not recommend it for the 503A compounding bulks list, citing immunogenicity and other safety concerns ^[1]. It is banned by WADA at all times. The human evidence base is limited to early pharmacology studies — no large or long-term trials for any indication.

This page reports what those studies found and what the safety literature says. It gives no dose and no advice.

What it is

CJC-1295 is a tetrasubstituted hGRF(1-29) analog: a peptide built on the first 29 residues of human growth-hormone-releasing factor (hGRF), carrying four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) that stabilize the alpha-helix, block DPP-IV cleavage, and prevent deamidation and oxidation. The result is a GHRH-like molecule that survives in plasma far longer than the native 44-residue hormone.

In the DAC variant (also called CJC-1295 DAC or DAC:GRF), a C-terminal lysine carries a maleimidopropionyl linker that reacts with the free thiol on Cys34 of circulating serum albumin, forming a covalent peptide-albumin conjugate. Albumin has a plasma half-life of roughly 19 days; the drug hitches onto it and stays in circulation for days.

The no-DAC variant (sold as Modified GRF 1-29 or Mod GRF 1-29) keeps the four stabilizing substitutions but lacks the albumin-binding handle. Its plasma half-life is hours, not days. These two forms behave very differently — water retention, sustained IGF-1 elevation, and other GH-related effects are more pronounced with the long-acting DAC form — and they are routinely conflated in community discussion and product labeling ^[7].

How it works

CJC-1295 binds the growth-hormone-releasing hormone receptor (GHRHR) on anterior-pituitary somatotroph cells, activating Gs-protein-coupled adenylate cyclase signaling: the cAMP / PKA cascade that stimulates synthesis and pulsatile release of endogenous GH. GH in turn acts on the liver and peripheral tissues to raise insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream anabolic and metabolic effects ^[1].

Because CJC-1295 is a receptor agonist rather than exogenous GH, the natural feedback mechanisms — somatostatin inhibition and IGF-1 negative feedback — remain intact and continue to limit runaway GH secretion. In a study of healthy men, GH pulsatility (the rhythm of natural GH bursts) was preserved even under continuous CJC-1295 stimulation: the frequency and amplitude of pulsatile GH secretion were not altered ^[5]. The DAC form keeps the receptor activated for days, while the no-DAC form provides a shorter-duration pulse.

The pharmacokinetics were established in rats and confirmed in early human trials. In rats, hGRF(1-29)-albumin bioconjugates (the DAC design) produced a 4-fold increase in GH AUC over 2 hours versus unconjugated peptide, and CJC-1295 was detectable in plasma beyond 72 hours ^[7].

What the research shows

The published human evidence for CJC-1295 is narrow but mechanistically clean.

Sustained GH and IGF-1 elevation in healthy adults. In the pivotal pharmacology study, single subcutaneous doses of 30 or 60 mcg/kg in healthy adults (ages 21-61) produced dose-dependent 2- to 10-fold increases in mean plasma GH sustained for 6 or more days, and 1.5- to 3-fold increases in IGF-1 sustained for 9-11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated CJC-1295 half-life was 5.8-8.1 days ^[4].

Pulsatility preserved. In healthy young men (ages 20-40) given a single subcutaneous dose of CJC-1295 at 60 or 90 mcg/kg, trough/basal GH rose approximately 7.5-fold and mean GH rose 46%, with IGF-1 up 45% one week later — but the frequency and magnitude of pulsatile GH bursts were unaltered, indicating the natural pattern of GH secretion persists under long-acting GHRH-analog stimulation ^[5].

Serum proteomic signatures. In 11 healthy young men, CJC-1295 administration shifted the serum proteome in a pattern correlated linearly with IGF-1 — decreased apolipoprotein A1 and a transthyretin isoform, increased albumin fragment and immunoglobulin species — identifying candidate biomarkers of GH/IGF-1 axis activation ^[3].

Animal baseline. In GHRH-knockout mice, once-daily CJC-1295 fully normalized body weight and length, while less frequent dosing was progressively inferior, and treated animals showed increased pituitary GH mRNA ^[6].

Anti-doping context. High-resolution LC-MS/MS identified CJC-1295 as the active ingredient in an unknown pharmaceutical preparation seized in an anti-doping case — establishing the compound's detectability by forensic methods ^[2].

The 2025 Nature Reviews Endocrinology review provides the current synthesis of GHRH-analog pharmacology and therapeutic context for the entire class ^[1].

Reported effects, cautions & safety

The following reflects what research-use communities report and what the cited literature says about safety. Anecdotal community reports are clearly labeled as such and are not clinical evidence.

What people in research-use communities commonly report (anecdotal, not clinical evidence):

• Deeper, more restful sleep — the single most commonly reported benefit, frequently described as noticeable within the first week. This fits the known biology: GH is secreted mainly during deep slow-wave sleep. Anecdotal, not a trial result.
• Faster recovery between hard workouts — frequently reported. People describe less lingering soreness and readier legs the next session. Could also reflect better sleep and normal training adaptation.
• Gradual fat loss around the midsection — frequently reported over weeks three to six of use, usually alongside diet and exercise. These are personal impressions, not clinical measurements.
• Leaner appearance and better muscle retention while dieting — occasionally reported, typically described as slow and subtle, contingent on consistent training and nutrition.
• Water retention, puffiness, and carpal-tunnel-like tingling — the most commonly reported adverse effects. Communities note both are more pronounced with the long-acting DAC form, because sustained GH elevation drives sodium and fluid retention, which can press on nerves. Reports say it often eases over a few weeks.
• Flushing or a 'head rush' shortly after injecting — occasionally reported, more with the no-DAC form around injection time, typically resolving within minutes.
• Higher blood sugar or reduced insulin sensitivity — occasionally reported, particularly flagged as a concern for people with existing metabolic issues or during prolonged continuous use. GH is glucose-sparing by mechanism.

Safety cautions from the cited literature:

• Not approved for human use anywhere. CJC-1295 has never been approved by the FDA or any other major regulator. It is sold only as a research chemical. Published human evidence is limited to early pharmacology studies; there are no large or long-term trials showing safety or efficacy in healthy adults ^[4].
• Not recommended for 503A compounding. The FDA reviewed CJC-1295 at the October 2024 Pharmacy Compounding Advisory Committee. The committee did not recommend it for the 503A compounding bulks list, citing immunogenicity and other safety concerns ^[1]. This means CJC-1295 is not listed for eligible compounding in the same category as, for example, sermorelin.
• Sustained IGF-1 elevation and cancer risk. CJC-1295 raises IGF-1 for days after a dose. Epidemiologic data link chronically higher circulating IGF-1 to a modestly increased risk of certain cancers. For anyone with a personal or family history of cancer, or an active or undiagnosed tumor, this is a mechanism-based concern rather than a settled risk estimate ^[1].
• Fluid retention and metabolic effects. Growth hormone makes kidneys retain sodium and water — the mechanism behind fluid retention, puffiness, and nerve-compression tingling. GH also opposes insulin, which can reduce insulin sensitivity and raise blood sugar. These are not hypothetical; they are cited physiologic consequences of sustained GH-axis stimulation ^[4].
• Discontinued development program. The original long-acting DAC program ran a Phase 2 trial that was discontinued, and a patient death during the development era is frequently cited. The public record does not establish that CJC-1295 caused that death, but the compound never advanced to approval ^[7].
• DAC and no-DAC are not the same thing. Community forums and product listings routinely conflate the DAC and no-DAC forms, but their pharmacokinetics are entirely different: days of action versus hours. The safety profile follows the duration ^[7].
• Banned in sport at all times. CJC-1295 is prohibited under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is detectable by established LC-MS/MS methods ^[2]. Any tested athlete risks an anti-doping violation.

Where it fits on the GH-axis desk

Among the two peptides on this desk, CJC-1295 is the pharmacologically bolder design — engineered to keep the GH axis firing for days rather than hours. That sustained action is what makes its human pharmacology data striking and what makes its safety concerns most concrete: prolonged fluid retention, prolonged IGF-1 elevation, prolonged glucose-sparing. It is also the compound with the more ambiguous regulatory status: not approved, not recommended for compounding, and with a halted development history.

Sermorelin, by contrast, is the simpler and longer-credentialed molecule — once an approved drug, now a compounded one, with a larger clinical trial record and feedback-regulated pulsatile GH release. Reading them side by side on the comparison page makes the tradeoffs concrete.